Natural product Pulsatilla saponin D sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgaf006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Shengbin Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biopharmacy, China Pharmaceutical University, Nanjing, P.R. China. Hauptthemen laut MEDLINE: Saponins, Ovarian Neoplasms, Pulsatilla, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Background
As a strategy in the development of effective cancer therapeutics, synthetic lethality has been used in clinical practice. Poly adenosine diphosphate (ADP)-ribose polymerase inhibitors are the first approved drug utilized synthetic lethality and achieved promising therapeutic efficacy in cancer cells with BRCA1/2 mutation. Nonetheless, most cancer patients with wild-type BRCA1/2 gene are not qualified for PARPi therapy. To induce BRCAness phenotype in cancer cells with normal BRCA1/2 status, we identified Pulsatilla Saponin D (SB365), which efficiently inhibited recruitment of BRCA1 at DNA double-strand breaks, leading to homologous recombination repair deficiency.
Methods
We utilized the HR repair reporter system. The reporter cells were treated with a natural compounds library to identify the agent that significantly decreased HR activity. Then, we detected the expression of HR related proteins using immunofluorescence and western blot. Colony formation and CCK8 was used to detect the inhibitory effect of Pulsatilla Saponin D on cell proliferation. Apoptosis was measured using Annexin V/PI staining. Comet assay kits were used to carry out the comet assay. Ovarian cancer xenograft model, immunohistochemical staining and Hematoxylin-Eosin staining was used to detect the antitumor efficacy and toxicity of Pulsatilla Saponin D. Key findings Pulsatilla Saponin D greatly increased PARPi-induced DNA DSBs, growth inhibition and apoptosis in ovarian cancer cells. Combined administration of PARPi and Pulsatilla Saponin D induced synergistic anti-tumor effects in ovarian cancer cells and xenograft mouse model without obvious toxicity.
Conclusions
In summary, our study found Pulsatilla Saponin D is a novel HR repair inhibitor and would optimize clinical application of PARP inhibitors on cancer patients with WT BRCA1/2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biopharmacy, China Pharmaceutical University, Nanjing, P.R. China.
- Department of Clinical Laboratory, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
- Department of Oncology, Jurong Hospital Affiliated to Jiangsu University, Zhenjiang, P.R. China.
- Department of Gynecology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangdong, P.R. China.
ORCID-Profile: Guo Chen
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Lin, S., Sun, B., Zhu, Y., Huang, Y., Qin, Y., Yao, N., Liu, Y., & Chen, G. (2025). Natural product Pulsatilla saponin D sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf006
Vancouver
Lin S, Sun B, Zhu Y, Huang Y, Qin Y, Yao N, et al. Natural product Pulsatilla saponin D sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf006
BibTeX
@article{Lin2025,
author = {Lin, Shengbin and Sun, Binghe and Zhu, Yin and Huang, Yi and Qin, Yu and Yao, Nan and Liu, Yongzhu and Chen, Guo},
title = {Natural product Pulsatilla saponin D sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgaf006}
}
EUVIMED